Novo Nordisk Projects Slower Growth
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
Novo Nordisk Q4 Profit Beats Expectations, Sees Slower Growth in 2025
LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns that the company is losing its edge in the competitive obesity market to rival Eli Lilly.
Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
20m
Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark — This company ...
Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion.
LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...
Novo Nordisk witnessed a significant uptick in its share price during European trading on Friday following the announcement ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk has projected slower growth after Wegovy sales more than doubled, amid competition from Eli Lilly. Though shares rose following improved earnings, concerns linger about U.S. demand.
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback